Vonoprazan (TAK-438 free base) is a potent, oral potassium-competitive acid blocker (P-CAB) that potently inhibits H+,K+-ATPase with IC50 of 19 nM.
Vonoprazan completely inhibits basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats (4mg/kg, p.o.).
Vonoprazan increases the pH of gastric perfusate to a higher value, and sustains longer than those of lansoprazole or SCH28080.
Vonoprazana is a clinical candidate for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer, and other acid-related diseases.
